Showing results (1461-1470 of 1,523) with videos related to
Sort By:
Pageof 153
Lung Cancer (Amsterdam, Netherlands)|January 30, 2022
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancerJianhua Chang, Yi-Long Wu, Shun Lu, et al.Cancer Discovery|May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.Stroke and Vascular Neurology|August 19, 2022
Temporal trends and rural-urban disparities in cerebrovascular risk factors, in-hospital management and outcomes in ischaemic strokes in China from 2005 to 2015: a nationwide serial cross-sectional surveyChun-Juan Wang, Hong-Qiu Gu, Xin-Miao Zhang, et al.The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.Molecular Neurobiology|November 2, 2018
Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving ChemotherapyChia Jie Tan, Sheree Wan Ting Lim, Yi Long Toh, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled TrialYang-Si Li, Qitao Yu, Qing Bu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2023
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical OutcomesChang Lu, Xue-Wu Wei, Zhen Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung CancerGlenwood D Goss, Gail E Darling, Virginie Westeel, et al.Pageof 153